{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:34:49Z","timestamp":1794486889659,"version":"4.9.1"},"reference-count":41,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"unspecified","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2026,2,19]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Asthma is a heterogeneous condition and affected individuals show variable responses to available medications. An unmet need exists for add-on therapies that target novel molecular pathways, before patients escalate to biologics. Janus kinase 1 (JAK1) is implicated in multiple inflammatory cytokine pathways critical for the pathogenesis of asthma. Londamocitinib (AZD4604) is a highly specific, inhaled, JAK1 inhibitor with high potency to block multiple JAK1-dependent signalling pathways. AJAX is a phase 2a, randomised, double-blind, partially decentralised placebo-controlled study assessing the efficacy, safety and pharmacokinetics (PK) of londamocitinib in adults with moderate-to-severe asthma uncontrolled on medium-to-high-dose inhaled corticosteroid\/long-acting \u03b2\n                      <jats:sub>2<\/jats:sub>\n                      -agonist.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The primary endpoint is time to first CompEx Asthma event. Secondary endpoints include change from baseline in prebronchodilator forced expiratory volume in 1\u2009s, chronic airways assessment test, six-item asthma control questionnaire, daily asthma symptom score, and morning and evening peak expiratory flow at weeks 4 and 12. In addition, assessment of the effect of londamocitinib on airway inflammation as measured by the fractional exhaled nitric oxide test; cough severity assessment; and the PK of londamocitinib in all participants after 4 and 12 weeks will also be evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study has received ethical approval from the appropriate ethic committee and will be conducted in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines, and all applicable regulatory requirements. All participants will provide written informed consent prior to enrolment, with procedures in place to ensure comprehension and voluntary participation. Findings will be disseminated through peer\u2011reviewed publications and\/or presentations at scientific conferences. Summary results will be posted on the trial registry and shared with participants and relevant patient groups in lay summaries.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2025-003589","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:35:15Z","timestamp":1772807715000},"page":"e003589","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Phase 2a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of londamocitinib (AZD4604) two times per day for 12 weeks in adult patients with moderate-to-severe asthma uncontrolled on medium-high-dose ICS-LABA"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct06020014","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01914757","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01928771","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06020014","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01914757","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01928771","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2781-1523","authenticated-orcid":false,"given":"Mohd Nubli","family":"Mustapa","sequence":"first","affiliation":[{"name":"Early Respiratory and Immunology Clinical Development, BioPharmaceuticals R&D, AstraZeneca Cambridge Biomedical Campus, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rod","family":"Hughes","sequence":"additional","affiliation":[{"name":"Early Respiratory and Immunology Clinical Development, BioPharmaceuticals R&D, AstraZeneca Cambridge Biomedical Campus, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina J","family":"Jensen","sequence":"additional","affiliation":[{"name":"Early Respiratory and Immunology Clinical Development, BioPharmaceuticals R&D, AstraZeneca AB, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davinder P","family":"Dosanjh","sequence":"additional","affiliation":[{"name":"Early Respiratory and Immunology Clinical Development, BioPharmaceuticals R&D, AstraZeneca Cambridge Biomedical Campus, Cambridge, UK"},{"name":"Birmingham Acute Care Research, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriakos V","family":"Konstantinidis","sequence":"additional","affiliation":[{"name":"Early Research & Development, Respiratory & Immunology, AstraZeneca Cambridge Biomedical Campus, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Jonsson","sequence":"additional","affiliation":[{"name":"Clinical Operations, BioPharmaceuticals R&D, AstraZeneca AB, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szil\u00e1rd","family":"Nemes","sequence":"additional","affiliation":[{"name":"Data Science & AI, BioPharmaceuticals R&D, AstraZeneca AB, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zala","family":"Jevnikar","sequence":"additional","affiliation":[{"name":"Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca AB, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jones","sequence":"additional","affiliation":[{"name":"Digital Health, Strategy and Implementation, Evinova, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Adams","sequence":"additional","affiliation":[{"name":"Patient Advisor, London, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G","family":"Belvisi","sequence":"additional","affiliation":[{"name":"Respiratory Pharmacology, National Heart and Lung Institute, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Akuthota","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of California San Diego, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janwillem W H","family":"Kocks","sequence":"additional","affiliation":[{"name":"General Practitioners Research Institute, Groningen, The Netherlands"},{"name":"Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Centre Groningen, Groningen, The Netherlands"},{"name":"Observational and Pragmatic Research Institute, Singapore"},{"name":"Department of Pulmonology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"2026030606350559000_13.1.e003589.1","unstructured":"Asthma GIf . Global strategy for asthma management and prevention. 2025. Available: www.ginasthma.org"},{"key":"2026030606350559000_13.1.e003589.2","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0075-2021","article-title":"Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD","volume":"30","author":"Miravitlles","year":"2021","journal-title":"Eur Respir Rev"},{"key":"2026030606350559000_13.1.e003589.3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.rmed.2016.09.015","article-title":"Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: Effect of drug, dose, and device","volume":"120","author":"Dekhuijzen","year":"2016","journal-title":"Respir Med"},{"key":"2026030606350559000_13.1.e003589.4","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1016\/j.jaip.2022.05.031","article-title":"The Contribution of Oral and Inhaled Glucocorticoids to Adrenal Insufficiency in Asthma","volume":"10","author":"Brennan","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026030606350559000_13.1.e003589.5","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2020-000756","article-title":"Systemic adverse effects from inhaled corticosteroid use in asthma: a systematic review","volume":"7","author":"Patel","year":"2020","journal-title":"BMJ Open Resp Res"},{"key":"2026030606350559000_13.1.e003589.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.108960"},{"key":"2026030606350559000_13.1.e003589.7","article-title":"Addition of long-acting beta2 agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta-analysis","volume":"8","author":"Oba","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2026030606350559000_13.1.e003589.8","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3389\/fped.2019.00246","article-title":"Epidemiology of Asthma in Children and Adults","volume":"7","author":"Dharmage","year":"2019","journal-title":"Front Pediatr"},{"key":"2026030606350559000_13.1.e003589.9","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"2026030606350559000_13.1.e003589.10","doi-asserted-by":"publisher","DOI":"10.1002\/pro.3519"},{"key":"2026030606350559000_13.1.e003589.11","unstructured":"Role of interferon-gamma as a marker of asthma severity and control. In: Allergy and immunology. 2019."},{"key":"2026030606350559000_13.1.e003589.12","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00099.2015"},{"key":"2026030606350559000_13.1.e003589.13","doi-asserted-by":"crossref","first-page":"717962","DOI":"10.3389\/fmolb.2021.717962","article-title":"STAT3 and IL-6 Contribute to Corticosteroid Resistance in an OVA and Ozone-induced Asthma Model with Neutrophil Infiltration","volume":"8","author":"Xue","year":"2021","journal-title":"Front Mol Biosci"},{"key":"2026030606350559000_13.1.e003589.14","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201"},{"key":"2026030606350559000_13.1.e003589.15","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/cea.12587","article-title":"Allergen\u2010induced early and late asthmatic responses to inhaled seasonal and perennial allergens","volume":"45","author":"Boulet","year":"2015","journal-title":"Clin Experimental Allergy"},{"key":"2026030606350559000_13.1.e003589.16","doi-asserted-by":"crossref","first-page":"13400","DOI":"10.1021\/acs.jmedchem.3c00554","article-title":"Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization","volume":"66","author":"Nilsson","year":"2023","journal-title":"J Med Chem"},{"key":"2026030606350559000_13.1.e003589.17","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.2147\/DDDT.S354291","article-title":"Characterization of Selective and Potent JAK1 Inhibitors Intended for the Inhaled Treatment of Asthma","volume":"16","author":"Nilsson","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"2026030606350559000_13.1.e003589.18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2023.11.323","article-title":"AZD4604, An Inhaled, Selective JAK1 Inhibitor Reduces Fractional Exhaled Nitric Oxide in Patients with Mild Asthma; A Randomized, Single-Blind Phase 1 Study","volume":"153","author":"Jensen","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"2026030606350559000_13.1.e003589.19","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S2213-2600(17)30218-7","article-title":"A novel endpoint for exacerbations in asthma to accelerate clinical development: a post-hoc analysis of randomised controlled trials","volume":"5","author":"Fuhlbrigge","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026030606350559000_13.1.e003589.20","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00246-2020","article-title":"Impact of season and geography on CompEx Asthma: a composite end-point for exacerbations","volume":"6","author":"Jauhiainen","year":"2020","journal-title":"ERJ Open Res"},{"key":"2026030606350559000_13.1.e003589.21","unstructured":"AstraZeneca . Phase 2a study to assess the efficacy and safety of AZD4604 in adult patients with moderate-to-severe asthma uncontrolled on medium-high dose ICS-LABA (AJAX). 2025. Available: https:\/\/clinicaltrials.gov\/study\/NCT06020014?term=NCT06020014&rank=1 [Accessed 14 Jan 2026]."},{"key":"2026030606350559000_13.1.e003589.22","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.01025-2023","article-title":"Use of CompEx in eosinophilic patients with severe, uncontrolled asthma on benralizumab","volume":"10","author":"Bolton","year":"2024","journal-title":"ERJ Open Res"},{"key":"2026030606350559000_13.1.e003589.23","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00470-2025","article-title":"CompEx Asthma: is it time for a change in clinical trials?","volume":"66","author":"Wilkinson","year":"2025","journal-title":"Eur Respir J"},{"key":"2026030606350559000_13.1.e003589.24","unstructured":"AstraZeneca . Efficacy and safety study of benralizumab in adults and adolescents inadequately controlled on inhaled corticosteroid plus long-acting \u03b22 agonist (CALIMA). 2025. Available: https:\/\/clinicaltrials.gov\/study\/NCT01914757 [Accessed 14 Jan 2026]."},{"key":"2026030606350559000_13.1.e003589.25","unstructured":"AstraZeneca . Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma (SIROCCO). 2017. Available: https:\/\/clinicaltrials.gov\/study\/NCT01928771?term=NCT01928771&rank=1 [Accessed 14 Jan 2026]."},{"key":"2026030606350559000_13.1.e003589.26","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1177\/1740774518770661","article-title":"Beyond p-values: A phase II dual-criterion design with statistical significance and clinical relevance","volume":"15","author":"Roychoudhury","year":"2018","journal-title":"Clin Trials"},{"key":"2026030606350559000_13.1.e003589.27","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-023-02394-6","article-title":"Chronic Airways Assessment Test: psychometric properties in patients with asthma and\/or COPD","volume":"24","author":"Tomaszewski","year":"2023","journal-title":"Respir Res"},{"key":"2026030606350559000_13.1.e003589.28","article-title":"Validation of the Chronic Airways Assessment Test in the NOVELTY Study","volume":"203","author":"Tomaszewski","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030606350559000_13.1.e003589.29","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1016\/j.jacc.2020.09.544","article-title":"Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel","volume":"76","author":"Psotka","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026030606350559000_13.1.e003589.30","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jacbts.2021.01.011","article-title":"Decentralized Clinical Trials: The Future of Medical Product Development?\u2217","volume":"6","author":"Van Norman","year":"2021","journal-title":"JACC Basic Transl Sci"},{"key":"2026030606350559000_13.1.e003589.31","unstructured":"U.S. Food and Drug Administration . The evolving role of decentralized clinical trials and digital health technologies. Available: https:\/\/www.fda.gov\/drugs\/cder-conversations\/evolving-role-decentralized-clinical-trials-and-digital-health-technologies [Accessed Jul 2024]."},{"key":"2026030606350559000_13.1.e003589.32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.20053","article-title":"Association of Remote Technology Use and Other Decentralization Tools With Patient Likelihood to Enroll in Cancer Clinical Trials","volume":"5","author":"Adams","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026030606350559000_13.1.e003589.33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s11673-024-10341-3","article-title":"Ethical Considerations in Decentralized Clinical Trials","volume":"20","author":"Bierer","year":"2023","journal-title":"J Bioeth Inq"},{"key":"2026030606350559000_13.1.e003589.34","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.1081150","article-title":"Decentralized clinical trials (DCTs): A few ethical considerations","volume":"10","author":"Petrini","year":"2022","journal-title":"Front Public Health"},{"key":"2026030606350559000_13.1.e003589.35","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.9120-11ST"},{"key":"2026030606350559000_13.1.e003589.36","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-201458"},{"key":"2026030606350559000_13.1.e003589.37","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00561-2019","article-title":"Bronchodilator reversibility in asthma and COPD: findings from three large population studies","volume":"54","author":"Janson","year":"2019","journal-title":"Eur Respir J"},{"key":"2026030606350559000_13.1.e003589.38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2019.04.014","article-title":"Comparison of the novel CompEx asthma exacerbation endpoint to the ATS\/ERS adapted moderate\/severe asthma exacerbation definition used in the MITRA trial","volume":"153","author":"Eriksson","year":"2019","journal-title":"Respir Med"},{"key":"2026030606350559000_13.1.e003589.39","article-title":"Effect of tezepelumab on a composite of severe asthma exacerbations and acute worsening events, CompEx, in the phase 3 NAVIGATOR study","volume":"77","author":"Brusselle","year":"2022","journal-title":"Thorax"},{"key":"2026030606350559000_13.1.e003589.40","article-title":"Results of a Phase 2b Dose Finding Study of Velsecorat, an Inhaled Non-Steroidal, Selective Glucocorticoid Receptor Modulator in Asthma (GRANIT)","volume":"203","author":"Chupp","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030606350559000_13.1.e003589.41","doi-asserted-by":"crossref","DOI":"10.7326\/L22-0490","article-title":"Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update","volume":"176","author":"DeTora","year":"2023","journal-title":"Ann Intern Med"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2025-003589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:35:21Z","timestamp":1772807721000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2025-003589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,6]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/bmjresp-2025-003589"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2025-003589","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}